Newsbenzinga
Anixa Biosciences Completes Dosing Of Fifth Group In Its Phase 1 Clinical Study Of FSHR-Targeted CAR-T Therapy To Treat Ovarian Cancer
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…